DURHAM, N.C., May 7, 2026
Atsena Therapeutics announced positive new clinical data from its investigational gene therapy programs ATSN-201 for X-linked retinoschisis (XLRS) and ATSN-101 for Leber congenital amaurosis type 1 (LCA1) during presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado. The company presented encouraging long-term efficacy and safety findings from both programs, reinforcing its position as one of the few ocular gene therapy companies advancing two inherited retinal disease candidates into pivotal-stage development. The data demonstrated durable structural and functional vision improvements across multiple patient populations, while additional research highlighted advancements in functional vision assessment tools designed to better measure treatment outcomes in inherited retinal diseases. Atsena stated that both ATSN-201 and ATSN-101 are expected to enter pivotal clinical trials during 2026 as the company accelerates development of potential one-time treatments for severe genetic blindness disorders.
ATSN-201 Demonstrates Durable Benefits in X-Linked Retinoschisis
The company’s ARVO presentation included 12-month data from Part A of the ongoing Phase 1/2/3 LIGHTHOUSE Trial evaluating ATSN-201 in adult patients with X-linked retinoschisis, a rare inherited retinal disease caused by mutations in the RS1 gene that leads to progressive vision loss and eventual blindness. According to the results presented by investigators from Oregon Health & Science University, ATSN-201 continued to demonstrate a favorable safety and tolerability profile across all treated patients, with no drug-related serious adverse events, no dose-limiting toxicities, and no patient discontinuations reported during the study period.
Clinical findings showed sustained foveal schisis closure in seven of nine treated eyes at 12 months, representing structural improvements not observed in untreated control eyes. Researchers also reported statistically significant improvements in best-corrected visual acuity, microperimetry, and low-luminance visual acuity, indicating meaningful recovery in retinal and visual function following treatment. Atsena emphasized that ATSN-201 is currently the first XLRS gene therapy program to demonstrate both safety and preliminary efficacy in clinical development.
The investigational therapy utilizes the company’s proprietary AAV.SPR capsid platform, which is specifically engineered to efficiently target photoreceptors in the central retina while minimizing surgical risks associated with foveal detachment. ATSN-201 has received multiple FDA regulatory designations, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting the significant unmet need in XLRS treatment. Atsena confirmed that patient screening is currently underway for the pivotal Phase 3 portion of the LIGHTHOUSE study, with enrollment expected to complete in early 2027 and a Biologics License Application filing targeted for 2028.
Advertisement
ATSN-101 Shows Durable Vision Improvements Through Three Years
A second major ARVO presentation highlighted three-year clinical data from the company’s Phase 1/2 trial of ATSN-101 in patients with Leber congenital amaurosis type 1, a severe inherited retinal disease caused by mutations in the GUCY2D gene that results in profound early-life visual impairment or blindness. According to the study findings presented by researchers from the University of Pennsylvania’s Scheie Eye Institute, patients treated with high-dose ATSN-101 maintained durable functional vision improvements through at least three years following treatment.
Investigators reported approximately 20 decibel improvements in dark-adapted full-field stimulus testing, representing nearly a 100-fold increase in light sensitivity compared with baseline measurements. The therapy also maintained a favorable long-term safety profile, with no drug-related serious adverse events or patient discontinuations reported during extended follow-up. Atsena stated that the durability of these findings supports plans to initiate a global pivotal Phase 3 trial for ATSN-101 during the second half of 2026.
In addition to the clinical data, Atsena also presented research involving a modified multi-luminance mobility test known as modMLMT, which was developed to better assess functional vision improvements in patients with retained rod photoreceptor activity. The company reported that the modified assessment captured treatment effects more effectively than standard mobility testing approaches and plans to incorporate the new methodology into future pivotal studies evaluating ATSN-101.
Gene Therapy Pipeline Expands Across Multiple Retinal Diseases
Atsena Therapeutics continues to position itself within the rapidly growing inherited retinal disease gene therapy sector, where biotechnology companies are increasingly pursuing one-time genetic treatments capable of restoring vision or preventing blindness progression. In addition to ATSN-201 and ATSN-101, the company’s pipeline includes investigational programs targeting Usher Syndrome Type 1B and Stargardt Disease, further expanding its focus on severe inherited retinal disorders with limited or no approved therapies.
Company executives stated that the ARVO 2026 data presentations reinforce confidence in the scalability, durability, and long-term therapeutic potential of its ocular gene therapy platform. As multiple retinal gene therapy programs progress into late-stage development globally, Atsena’s upcoming pivotal studies may play an important role in shaping the future competitive landscape for inherited blindness treatments.
Source: Atsena Therapeutics press release
